Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial

BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) improve cardiovascular and renal outcomes in patients with type 2 diabetes through distinct mechanisms. However, evidence on clinical outcomes in patients treated with both GLP-1 R...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cardiovasc Diabetol
Päätekijät: Clegg, Lindsay E., Penland, Robert C., Bachina, Srinivas, Boulton, David W., Thuresson, Marcus, Heerspink, Hiddo J. L., Gustavson, Stephanie, Sjöström, C. David, Ruggles, James A., Hernandez, Adrian F., Buse, John B., Mentz, Robert J., Holman, Rury R.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2019
Aiheet:
Original Investigation
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6805385/
https://ncbi.nlm.nih.gov/pubmed/31640705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-019-0942-x
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia